Cargando…

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

BACKGROUND: Monoclonal antibodies anti-calcitonin gene-related peptide (mAbs anti-CGRP) pathway are effective and safe on migraine prevention. However, some drug agencies limited these treatments to one year due to their high costs. This study aimed at evaluating the effect of discontinuing mAbs ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vernieri, Fabrizio, Brunelli, Nicoletta, Messina, Roberta, Costa, Carmelina Maria, Colombo, Bruno, Torelli, Paola, Quintana, Simone, Cevoli, Sabina, Favoni, Valentina, d’Onofrio, Florindo, Egeo, Gabriella, Rao, Renata, Filippi, Massimo, Barbanti, Piero, Altamura, Claudia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Milan 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8903705/ https://www.ncbi.nlm.nih.gov/pubmed/34922444 http://dx.doi.org/10.1186/s10194-021-01363-y

Ejemplares similares

Locking down the CGRP pathway during the COVID-19 pandemic lockdown: the PandeMig study
por: Altamura, Claudia, et al.
Publicado: (2020)

Predictors of response to anti-CGRP monoclonal antibodies: a 24-week, multicenter, prospective study on 864 migraine patients
por: Barbanti, Piero, et al.
Publicado: (2022)

Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)
por: Vernieri, Fabrizio, et al.
Publicado: (2021)

Conversion from chronic to episodic migraine in patients treated with galcanezumab in real life in Italy: the 12-month observational, longitudinal, cohort multicenter GARLIT experience
por: Altamura, Claudia, et al.
Publicado: (2022)

Maintenance of response and predictive factors of 1‐year GalcanezumAb treatment in real‐life migraine patients in Italy: The multicenter prospective cohort GARLIT study
por: Vernieri, Fabrizio, et al.
Publicado: (2022)

Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
por: Pensato, Umberto, et al.
Publicado: (2022)

Correction to: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

Correction: Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

Fremanezumab in the prevention of high-frequency episodic and chronic migraine: a 12-week, multicenter, real-life, cohort study (the FRIEND study)
por: Barbanti, Piero, et al.
Publicado: (2022)

Change of CGRP Plasma Concentrations in Migraine after Discontinuation of CGRP-(Receptor) Monoclonal Antibodies
por: Raffaelli, Bianca, et al.
Publicado: (2023)

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study
por: Barbanti, Piero, et al.
Publicado: (2023)

A proposal for a national registry on chronic migraines
por: Vanacore, Nicola, et al.
Publicado: (2015)

Improving distress perception and mutuality in migraine caregivers after 6 months of galcanezumab treatment
por: Fofi, Luisa, et al.
Publicado: (2022)

Commentary: Enhanced Hemodynamic and Clinical Response to αCGRP in Migraine Patients—A TCD Study
por: Altamura, Claudia, et al.
Publicado: (2021)

Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine
por: Berman, Gary, et al.
Publicado: (2020)

Carotid Artery Plaque Progression: Proposal of a New Predictive Score and Role of Carotid Intima-Media Thickness
por: Brunelli, Nicoletta, et al.
Publicado: (2022)

Botulinum Neurotoxin for the Treatment of Neuropathic Pain
por: Egeo, Gabriella, et al.
Publicado: (2020)

Refractory migraine profile in CGRP‐monoclonal antibodies scenario
por: Silvestro, Marcello, et al.
Publicado: (2021)

A Randomized Clinical Trial on Acupuncture Versus Best Medical Therapy in Episodic Migraine Prophylaxis: The ACUMIGRAN Study
por: Giannini, Giulia, et al.
Publicado: (2021)

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?
por: Favoni, Valentina, et al.
Publicado: (2019)

Monoclonal antibodies against CGRP (R): non-responders and switchers: real world data from an austrian case series
por: Kaltseis, Katharina, et al.
Publicado: (2023)

Anti-CGRP Monoclonal Antibodies: the Next Era of Migraine Prevention?
por: Tso, Amy R., et al.
Publicado: (2017)

Inflammatory complications of CGRP monoclonal antibodies: a case series
por: Ray, Jason C., et al.
Publicado: (2021)

CGRP-monoclonal antibodies and SARS-CoV-2 vaccination
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

CGRP-monoclonal antibodies in difficult-to-treat chronic migraine patients
por: Schiano di Cola, Francesca, et al.
Publicado: (2022)

Gepants — a long way to cure: a narrative review
por: Altamura, Claudia, et al.
Publicado: (2022)

Chronic migraine: treatability, refractoriness, pseudo-refractoriness
por: Barbanti, Piero, et al.
Publicado: (2015)

Spotlight on Anti‐CGRP Monoclonal Antibodies in Migraine: The Clinical Evidence to Date
por: Pellesi, Lanfranco, et al.
Publicado: (2017)

“Triaging” Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies
por: Martelletti, Paolo
Publicado: (2020)

Monoclonal Antibodies Targeting CGRP: A Novel Treatment in Vestibular Migraine
por: Lovato, Andrea, et al.
Publicado: (2023)

Advances in CGRP Monoclonal Antibodies as Migraine Therapy: A Narrative Review
por: Aditya, Suruchi, et al.
Publicado: (2023)

Headache, anxiety and depressive disorders: the HADAS study
por: Beghi, Ettore, et al.
Publicado: (2010)

P044. Anger expression in chronic daily headache patients with and without psychiatric comorbidity
por: Giannini, Giulia, et al.
Publicado: (2015)

Eptinezumab for the Prevention of Migraine: Clinical Utility, Patient Preferences and Selection – A Narrative Review
por: Altamura, Claudia, et al.
Publicado: (2023)

CGRP monoclonal antibody for preventive treatment of chronic migraine: An update of meta‐analysis
por: Han, Lin, et al.
Publicado: (2019)

CGRP monoclonal antibodies in migraine: an efficacy and tolerability comparison with standard prophylactic drugs
por: Vandervorst, Fenne, et al.
Publicado: (2021)

Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
por: Simioni, Caio Vinicius de Meira Grava
Publicado: (2022)

It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
por: Kubota, Gabriel Taricani
Publicado: (2022)

P063. Colloid cysts of the third ventricle: a case report
por: de Pasqua, Silvia, et al.
Publicado: (2015)

Non-invasive vagus nerve stimulation for acute treatment of high-frequency and chronic migraine: an open-label study
por: Barbanti, Piero, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_8r3eguf66gvm2o5gat8bejsjdo